2015
DOI: 10.1097/coc.0000000000000223
|View full text |Cite
|
Sign up to set email alerts
|

The Trimodality Treatment Approach in Stage III/pN2 Non–Small Cell Lung Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
1
1

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“…Recent data on the use of modern postoperative TRT [22] seem to overcame negative impact of historic data [23,24], since it enabled effectively concentrating on patients harboring high risk features. In Stage IIIA NSCLC, less than a half of the institutions would still consider surgical multimodality approach likely due to a number of group/society guidelines and recommendations [25,26] in spite of the fact that serious criticism and a number of aws and fallacies have been highlighted in recent years [27][28][29][30]. In, inoperable cases, the vast majority of departments would prefer concurrent RT-CHT, following highest level of evidence existing for more than a decade [31][32][33].…”
Section: Discussionmentioning
confidence: 99%
“…Recent data on the use of modern postoperative TRT [22] seem to overcame negative impact of historic data [23,24], since it enabled effectively concentrating on patients harboring high risk features. In Stage IIIA NSCLC, less than a half of the institutions would still consider surgical multimodality approach likely due to a number of group/society guidelines and recommendations [25,26] in spite of the fact that serious criticism and a number of aws and fallacies have been highlighted in recent years [27][28][29][30]. In, inoperable cases, the vast majority of departments would prefer concurrent RT-CHT, following highest level of evidence existing for more than a decade [31][32][33].…”
Section: Discussionmentioning
confidence: 99%